Maximus, Inc. (NYSE:MMS) – Analysts at KeyCorp upped their FY2017 EPS estimates for Maximus in a research report issued to clients and investors on Thursday. KeyCorp analyst J. Gurda now anticipates that the health services provider will post earnings per share of $3.13 for the year, up from their prior forecast of $3.07. KeyCorp has a “Sector Weight” rating on the stock. KeyCorp also issued estimates for Maximus’ Q4 2017 earnings at $0.76 EPS.

Maximus (NYSE:MMS) last announced its quarterly earnings results on Thursday, August 3rd. The health services provider reported $0.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.76 by $0.03. Maximus had a net margin of 8.43% and a return on equity of 25.08%. The firm had revenue of $600.40 million for the quarter, compared to the consensus estimate of $614.12 million. During the same period in the prior year, the firm posted $0.79 earnings per share. The company’s revenue for the quarter was down 2.7% on a year-over-year basis. ILLEGAL ACTIVITY NOTICE: This article was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/08/07/fy2017-earnings-forecast-for-maximus-inc-issued-by-keycorp-mms.html.

A number of other equities research analysts also recently issued reports on MMS. Maxim Group downgraded Maximus from a “buy” rating to a “hold” rating and set a $66.00 price target for the company. in a research note on Thursday, May 4th. They noted that the move was a valuation call. Jefferies Group LLC cut Maximus from a “buy” rating to a “hold” rating and lifted their price objective for the company from $63.00 to $64.00 in a research report on Friday, May 5th. ValuEngine cut Maximus from a “buy” rating to a “hold” rating in a research report on Tuesday, May 16th. Canaccord Genuity cut Maximus from a “buy” rating to a “hold” rating and set a $62.00 price objective on the stock. in a research report on Tuesday, July 4th. Finally, BidaskClub cut Maximus from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 6th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the company’s stock. Maximus has a consensus rating of “Hold” and a consensus price target of $62.17.

Shares of Maximus (NYSE MMS) opened at 61.06 on Monday. The stock has a 50 day moving average of $61.91 and a 200-day moving average of $60.73. Maximus has a one year low of $43.69 and a one year high of $64.97. The stock has a market capitalization of $3.96 billion, a P/E ratio of 20.02 and a beta of 1.39.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 31st. Investors of record on Tuesday, August 15th will be issued a $0.045 dividend. The ex-dividend date of this dividend is Friday, August 11th. This represents a $0.18 dividend on an annualized basis and a yield of 0.29%. Maximus’s dividend payout ratio is presently 5.73%.

In related news, insider Mark Andrekovich sold 8,939 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $64.01, for a total value of $572,185.39. Following the transaction, the insider now directly owns 24,583 shares of the company’s stock, valued at approximately $1,573,557.83. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, President Bruce Caswell sold 8,000 shares of the business’s stock in a transaction that occurred on Thursday, July 27th. The stock was sold at an average price of $60.97, for a total value of $487,760.00. Following the completion of the transaction, the president now directly owns 35,904 shares in the company, valued at $2,189,066.88. The disclosure for this sale can be found here. Over the last three months, insiders sold 117,846 shares of company stock worth $7,381,746. 3.10% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Shell Asset Management Co. acquired a new position in Maximus during the first quarter worth approximately $542,000. Glen Harbor Capital Management LLC boosted its position in Maximus by 1.9% in the first quarter. Glen Harbor Capital Management LLC now owns 2,332 shares of the health services provider’s stock worth $145,000 after buying an additional 44 shares in the last quarter. Meritage Portfolio Management acquired a new position in Maximus during the first quarter worth approximately $5,668,000. Nationwide Fund Advisors boosted its position in Maximus by 16.9% in the first quarter. Nationwide Fund Advisors now owns 357,173 shares of the health services provider’s stock worth $22,216,000 after buying an additional 51,639 shares in the last quarter. Finally, Navellier & Associates Inc boosted its position in Maximus by 10.9% in the first quarter. Navellier & Associates Inc now owns 8,737 shares of the health services provider’s stock worth $543,000 after buying an additional 856 shares in the last quarter. 97.89% of the stock is currently owned by institutional investors.

Maximus Company Profile

MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.

Earnings History and Estimates for Maximus (NYSE:MMS)

Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.